AstraZeneca Revenue 2010-2024 | AZN
AstraZeneca annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- AstraZeneca revenue for the quarter ending September 30, 2024 was $13.565B, a 18.04% increase year-over-year.
- AstraZeneca revenue for the twelve months ending September 30, 2024 was $51.206B, a 13.8% increase year-over-year.
- AstraZeneca annual revenue for 2023 was $45.811B, a 3.29% increase from 2022.
- AstraZeneca annual revenue for 2022 was $44.351B, a 18.53% increase from 2021.
- AstraZeneca annual revenue for 2021 was $37.417B, a 40.58% increase from 2020.
AstraZeneca Annual Revenue
(Millions of US $) |
| 2023 |
$45,811 |
| 2022 |
$44,351 |
| 2021 |
$37,417 |
| 2020 |
$26,617 |
| 2019 |
$24,384 |
| 2018 |
$22,090 |
| 2017 |
$22,465 |
| 2016 |
$23,002 |
| 2015 |
$24,708 |
| 2014 |
$26,547 |
| 2013 |
$25,806 |
| 2012 |
$27,973 |
| 2011 |
$33,591 |
| 2010 |
$33,269 |
| 2009 |
$32,804 |
AstraZeneca Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$13,565 |
| 2024-06-30 |
$12,938 |
| 2024-03-31 |
$12,679 |
| 2023-12-31 |
$12,024 |
| 2023-09-30 |
$11,492 |
| 2023-06-30 |
$11,416 |
| 2023-03-31 |
$10,879 |
| 2022-12-31 |
$11,208 |
| 2022-09-30 |
$10,982 |
| 2022-06-30 |
$10,771 |
| 2022-03-31 |
$11,390 |
| 2021-12-31 |
$12,011 |
| 2021-09-30 |
$9,866 |
| 2021-06-30 |
$8,220 |
| 2021-03-31 |
$7,320 |
| 2020-12-31 |
$7,410 |
| 2020-09-30 |
$6,578 |
| 2020-06-30 |
$6,275 |
| 2020-03-31 |
$6,354 |
| 2019-12-31 |
$6,664 |
| 2019-09-30 |
$6,406 |
| 2019-06-30 |
$5,823 |
| 2019-03-31 |
$5,491 |
| 2018-12-31 |
$6,417 |
| 2018-09-30 |
$5,340 |
| 2018-06-30 |
$5,155 |
| 2018-03-31 |
$5,178 |
| 2017-12-31 |
$5,777 |
| 2017-09-30 |
$6,232 |
| 2017-06-30 |
$5,051 |
| 2017-03-31 |
$5,405 |
| 2016-12-31 |
$5,585 |
| 2016-09-30 |
$5,699 |
| 2016-06-30 |
$5,603 |
| 2016-03-31 |
$6,115 |
| 2015-12-31 |
$6,399 |
| 2015-09-30 |
$5,945 |
| 2015-06-30 |
$6,307 |
| 2015-03-31 |
$6,057 |
| 2014-12-31 |
$6,716 |
| 2014-09-30 |
$6,609 |
| 2014-06-30 |
$6,762 |
| 2014-03-31 |
$6,460 |
| 2013-12-31 |
$6,939 |
| 2013-09-30 |
$6,250 |
| 2013-06-30 |
$6,232 |
| 2013-03-31 |
$6,385 |
| 2012-12-31 |
$7,282 |
| 2012-09-30 |
$6,682 |
| 2012-06-30 |
$6,660 |
| 2012-03-31 |
$7,349 |
| 2011-12-31 |
$8,656 |
| 2011-09-30 |
$8,213 |
| 2011-06-30 |
$8,430 |
| 2011-03-31 |
$8,292 |
| 2010-12-31 |
$8,617 |
| 2010-09-30 |
$7,898 |
| 2010-06-30 |
$8,178 |
| 2010-03-31 |
$8,576 |
| 2009-12-31 |
$8,945 |
| 2009-09-30 |
$8,200 |
| 2009-06-30 |
$7,958 |
| 2009-03-31 |
$7,701 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$197.819B |
$45.811B |
|
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
|
